Ge Chunlei, Li Ruilei, Song Xin, Qin Shukui
Department of Cancer Biotherapy Center, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming 650118, China.
Department of Medical Oncology, PLA Cancer Center, Nanjing Bayi Hospital, Nanjing 210002, China.
Chin Clin Oncol. 2017 Apr;6(2):18. doi: 10.21037/cco.2017.02.07.
Adoptive cell therapy (ACT) has been developed in cancer treatment by transferring/infusing immune cells into cancer patients, which are able to recognize, target, and destroy tumor cells. Recently, sipuleucel-T and genetically-modified T cells expressing chimeric antigen receptors (CAR) show a great potential to control metastatic castration-resistant prostate cancer and hematologic malignancies in clinic. This review summarized some of the major evidence-based ACT and the challenges to improve cell quality and reduce the side effects in the field. This review also provided future research directions to make sure ACT widely available in clinic.
过继性细胞疗法（ACT）已被应用于癌症治疗，通过将免疫细胞转移/注入癌症患者体内，这些细胞能够识别、靶向并摧毁肿瘤细胞。最近，sipuleucel-T和表达嵌合抗原受体（CAR）的基因改造T细胞在临床上显示出控制转移性去势抵抗性前列腺癌和血液系统恶性肿瘤的巨大潜力。本综述总结了一些主要的循证ACT以及该领域中提高细胞质量和减少副作用所面临的挑战。本综述还提供了未来的研究方向，以确保ACT在临床上广泛应用。
